Docetaxel with ramucirumab or placebo for second-line treatment of stag

Lung Cancer Aug 11, 2017

Reck M et al. – Ramucirumab plus docetaxel was shown to be an appropriate treatment option for refractory patients with stage IV NSCLC.

Methods

The treatment effect of docetaxel with ramucirumab in patients refractory to prior first-line treatment was characterized.

Results

Of 1253 patients, 360 were refractory to first-line treatment.
Median OS (8.3 vs. 6.3 months; HR, 0.86), median PFS (4.0 vs. 2.5 months; HR, 0.71), and ORR (22.5% vs. 12.6%) were improved in refractory patients treated with ramucirumab compared to placebo.

Go to Original

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.

4 reasons why Doctors love M3 India